Sprache auswählen
Punkte tauschen
Mucin-1
Mucin-1 Molekülinformation
| Englischer Name | Mucin-1 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 22 | Target-Alias | PEM，Medullary Cystic Kidney Disease 1 (Autosomal Dominant)，Tumor Associated Epithelial Mucin，CD227 Antigen，H23 Antigen，MUC-1/SEC，ADMCKD1，Cancer antigen 15-3，Tumor-associated mucin，MUC1-alpha，MUC1-beta，MUC-1/X，MUC1/ZD，Mucin-1，ADMCKD，MCKD1，MAM6，MCKD，MCD，Polymorphic epithelial mucin，PUM，MUC1-NT，Episialin，CD227，MUC1-CT，MUC1，Mucin 1， Cell Surface Associated，Tumor-Associated Epithelial Membrane Antigen，Peanut-Reactive Urinary Mucin，Carcinoma-Associated Mucin，Krebs Von Den Lungen-6，CA 15-3，H23AG，MUC-1，KL-6，PEMT，EMA，Breast carcinoma-associated antigen DF3，Mucin 1， Transmembrane |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Mucin-1 |
| Target-Alias | PEM，Medullary Cystic Kidney Disease 1 (Autosomal Dominant)，Tumor Associated Epithelial Mucin，CD227 Antigen，H23 Antigen，MUC-1/SEC，ADMCKD1，Cancer antigen 15-3，Tumor-associated mucin，MUC1-alpha，MUC1-beta，MUC-1/X，MUC1/ZD，Mucin-1，ADMCKD，MCKD1，MAM6，MCKD，MCD，Polymorphic epithelial mucin，PUM，MUC1-NT，Episialin，CD227，MUC1-CT，MUC1，Mucin 1， Cell Surface Associated，Tumor-Associated Epithelial Membrane Antigen，Peanut-Reactive Urinary Mucin，Carcinoma-Associated Mucin，Krebs Von Den Lungen-6，CA 15-3，H23AG，MUC-1，KL-6，PEMT，EMA，Breast carcinoma-associated antigen DF3，Mucin 1， Transmembrane |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 22 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
Mucin-1 Produktliste
- Attribut
Protein (19)Antibody (1)Kits (1)
- Produktbibliothek
Online (21)
- Spezies
Human (13)Cynomolgus (5)Mouse (3)
- Etikett
Fc Tag (7)Llama IgG Fc Tag (1)His Tag (6)His Tag & Avi Tag (3)Mouse IgG Fc Tag (2)- (2)
- Marker
Unconjugated (16)Biotin-labeled (3)APC Labeled (1)- (1)
In den Warenkorb legen
Gesamtmenge21
- 1
- 2
- 3
Mucin-1 Molekülhintergrund
Membrane mucins have several functions in epithelial cells including cytoprotection, extravasation during metastases, maintenance of luminal structure, and signal transduction. MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites. Interacts via its C-terminus with PDZK1 and this interaction appears important for proper localization. Probably plays a role in maintaining homeostasis on mucosal surfaces.
Mucin-1 Molekülalias
Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1,SEC,MUC-1,X,MUC1,ZD,PEM,PEMT,PUM,CA15-3,Episialin
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Intestinal Neoplasms; Solid tumours; Cystadenocarcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| PD-1 Knockout Anti-MUC1 CAR-T Cells (Guangzhou Anjie Biomedical) | AJMUC1 | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology | Esophageal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-MUC1 monoclonal antibody (OncoQuest) | AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 | Phase 2 Clinical | Altarex | Pancreatic Neoplasms | Details |
| GO-2032c | GO-203-2C | Phase 2 Clinical | Genus Oncology Llc, Dana-Farber Cancer Institute | Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| MUC1-Poly-ICLC | MUC1-poly-ICLC | Phase 2 Clinical | University Of Pittsburgh | Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| DS-3939 | DS-3939a; DS-3939 | Phase 2 Clinical | Daiichi Sankyo Inc | Solid tumours | Details |
| BM7PE | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
| Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) | Phase 2 Clinical | The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney | Carcinoma, Non-Small-Cell Lung | Details | |
| huMNC2-CAR44 | huMNC2-CAR44 | Phase 1 Clinical | Minerva Biotechnologies Co | Metastatic breast cancer | Details |
| ICTCAR-052 | ICTCAR-052 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| Adenoviral MUC1 vaccine (Etubics) | ETBX-061; Ad5-MUC1 | Phase 1 Clinical | Etubics Corp, Immunitybio Inc, Nantkwest Inc | Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Chordoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck | Details |
| Gatipotuzumab | GT-MAB-2.5-GEX | Phase 1 Clinical | Nemod, Glycotope Gmbh | Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| P-MUC1C-ALLO1 | P-MUC1C-ALLO1; P-MUC1C-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ICTCAR-053 | ICTCAR-053 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
| BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeiGene (Beijing) Co Ltd | Solid tumours; Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
| MUC1-peptide-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| MUC1-gene-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| DM-002 | DM-002; DM002 (Danma) | Phase 1 Clinical | Danma (Suzhou) Biomedical Technology Co Ltd | Ovarian Neoplasms; Solid tumours; Prostatic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms | Details |
| Recombinant HSP-MUC1 fusion protein (Newsummit) | Phase 1 Clinical | Shanghai Xinshengyuan Biological Medicine Co Ltd | Breast Neoplasms | Details | |
| DXC-005 | DXC-005 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ICTCAR-046 | ICTCAR-046 | Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main